Expression Of NME4、Bnip3L、HKDC1 And Its Prognostic Value In Newly Diagnosed Supratentorial Glioblastoma

Part 1: Expression of NME4 and its prognostic value in newly diagnosed supratentorial glioblastomaNon-metastatic cells 4 protein,(NME4) Play a key role in the occurrence and progression of glioblastoma.However, it is still controversial whether NME4 expression is associated with the clinical outcome of glioblastoma patients. The aim of this study was to investigate NME4 expression in glioblastoma tissues, and explore the relationship between its expression and prognosis in patients with GBM. Such evidence would further illustrate whether NME4 protein inhibition is fit for clinical treatment. The expression of NME4 was examined in the tumor tissues from 70 patients with newly diagnosed supratentorial GBM via immunohistochemical technique. Its association with the clinicopathological characteristics was analyzed, and the Kaplan-Meier curve and COX proportional hazards regression model were sed to evaluate the influences of its expression on progression-free survival(PFS) and overall survival(OS). Immunohistochemical assay suggested increased expression of NME4 protein in glioblastoma tissue compared to the normal brain tissue around the tumor tissue without NME4 protein expression. There were no relationship between NME4 protein expression and patient gender(P = 0. 206), age(P = 0.467) and preoperative Karnofsky performance status(KPS)(P = 0.131). Univariate survival analysis indicated that significant association of high NME4 protein expression with shorter PFS(P<0.001) and OS(P<0.001). Multivariate survival analysis also indicated that high NME4 protein expression as a important prognostic indicator for shorter PFS and OS, have no relationship with patient’s KPS 、age or chemoradiotherapy. The high percentage of NME4 protein positive tumor tissue cells is a important independent prognostic indicator for poor clinical consequence in patients who suffers from GBM, except better age, poorer performance status and non-standard chemoradiotherapy project, and indicating that NME4 protein may be regarded as a hopeful therapeutic target in patients with GBM.Part 2: Expression of Bnip3 L and its prognostic value in newly diagnosed supratentorial glioblastomaBcl-2/E1B19 kDa inteareting Protein 3-like,(Bnip3L) Play a key role in the occurrence and progression of glioblastoma. However, it is still contradictory that whether Bnip3 L protein expression is in connection with the clinical outcome of glioblastoma patients. The aim of this study was to investigate Bnip3 L expression in glioblastoma tissues, and explore the relationship between its expression and prognosis in patients with GBM. Such evidence would further illustrate that whether Bnip3 L protein inhibition is fit for clinical treatment. The expression of Bnip3 L was examined in the tumor tissues from 70 patients with newly diagnosed upratentorial GBM via immunohistochemical technique. Its relationship with the clinicopathological characteristics was analyzed, and the Kaplan-Meier curve and COX proportional hazards regression model were used to evaluate the influences of its expression on progression-free survival(PFS) and overall survival(OS). Immunohistochemical assay suggested that increased expression of Bnip3 L protein in GBM tissue compared to normal brain tissue around the tumor tissue without Bnip3 L protein expression. There were no relationship between Bnip3 L protein expression and patient’s gender(P = 0. 314), age(P = 0.257) and preoperative Karnofsky performance status(KPS)(P =0.158). Univariate survival analysis indicated important association of high Bnip3 L protein expression with shorter PFS(P<0.001) or OS(P<0.001). Multivariate survival analysis revealed that high Bnip3 L protein expression as a impotant prognostic indicator for patient’s shorter PFS and OS, have no relationship with KPS 、age or chemoradiotherapy. The high percentage of Bnip3 L protein positive tumor tissue cells in patient with GBM is a significant independent prognostic suggestion for poorer clinical consequence in patients with GBM, ecxept advanced age, poorer performance status and non-standard chemoradiotherapy paln, and indicating that Bnip3 L may be serve as a prospective therapeutic target in patient with GBM.Part 3: Expression of HKDC1 and its prognostic value in newly diagnosed supratentorial glioblastomaHexokinase domain-containing protein 1,(HKDC1) Play a key role in the occurrence and progression of glioblastoma. However, it is still contradictory that whether HKDC1 protein expression is related with the clinical consequence of glioblastoma patients. The target of this assay was to investigate HKDC1 protein expression in glioblastoma tissues, and xplore the relationship between its expression and prognosis in patients with GBM. Such evidence would further illustrate whether HKDC1 protein inhibition is fit for clinical treatment. The expression of HKDC1 was examined in the tumor tissues from 70 patients with newly diagnosed supratentorial GBM via immunohistochemical technique. Its relationship with the tumor’s clinicopathological characteristics was analyzed, and the Kaplan-Meier curve and COX proportional hazards regression model were used to evaluate the influences of its expression on progression-free survival(PFS) and overall survival(OS). Immunohistochemical assay suggested that increased expression of HKDC1 protein in GBM tissue compared to normal brain around the toumor tissue without HKDC1 protein expression. There were no relationship between HKDC1 protein expression and patient’s gender(P=0.417), age(P=0. 332) and preoperative Karnofsky performance status(KPS)(P = 0.321). Univariate survival analysis indicated that important association of high HKDC1 protein expression with shorter PFS(P P=0.021) or OS(P=0.002). Multivariate survival analysis revealed that high HKDC1 protein expression can be as a important prognostic indicator for shorter PFS or OS, independent of age, KPS and chemoradiotherapy treatment. The high percentage of HKDC1 protein positive tumor tissue cells is a important independent prognostic indicator for poorer clinical consequence in patients with GBM, except advanced age, poorer performance status and non-standard chemoradiotherapy plan, and indicating that HKDC1 protein may be as a prospective therapeutic target in patient with GBM.